(CABA) Cabaletta Bio - Overview
Stock: CD19-CAR T, CAAR T, T Cell, Autoimmune
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 105% |
| Relative Tail Risk | -15.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.54 |
| Alpha | -15.94 |
| Character TTM | |
|---|---|
| Beta | 1.533 |
| Beta Downside | 1.398 |
| Drawdowns 3y | |
|---|---|
| Max DD | 95.90% |
| CAGR/Max DD | -0.43 |
Description: CABA Cabaletta Bio January 17, 2026
Cabaletta Bio, Inc. (NASDAQ:CABA) is a Philadelphia-based, clinical-stage biotech that engineers T-cell therapies to treat autoimmune disorders. The firm was incorporated in 2017 (originally Tycho Therapeutics) and rebranded in 2018.
Its flagship candidate, resecabtagene autoleucel (a fully human CD19-CAR T with a 4-1BB co-stimulatory domain), is currently enrolled in Phase 1/2 trials across a broad portfolio of autoimmune indications-including dermatomyositis, lupus nephritis, multiple sclerosis, and generalized myasthenia gravis. Additional pipelines include DSG3-CAART for mucosal pemphigus vulgaris (Phase 1) and MuSK-CAART for MuSK-positive myasthenia gravis (Phase 1).
The company leverages collaborations with academic and industry partners such as the University of Pennsylvania, Children’s Hospital of Philadelphia, Oxford Biomedica, Autolus Holdings, and WuXi Advanced Therapies, providing access to manufacturing capacity and clinical expertise.
As of the most recent 10-Q (Q3 2024), Cabaletta reported approximately $45 million in cash and equivalents, supporting an estimated 12-month cash runway given its quarterly burn of roughly $12 million. The broader CAR-T market is projected by Grand View Research to exceed $13 billion by 2028, while the global autoimmune disease therapeutics market is growing at a CAGR of ~7 % driven by rising prevalence and unmet patient needs-both macro trends that underpin Cabaletta’s strategic focus.
For a deeper, data-driven look at how Cabaletta’s valuation compares to sector peers, you might find ValueRay’s analytical dashboards worth a quick glance.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -158.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.63 > 0.02 and ΔFCF/TA -22.49 > 1.0 |
| NWC/Revenue: 7254 % < 20% (prev 4056 %; Δ 3199 % < -1%) |
| CFO/TA -0.63 > 3% & CFO -118.9m > Net Income -158.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (102.3m) vs 12m ago 106.7% < -2% |
| Gross Margin: -7.81% > 18% (prev 0.61%; Δ -842.1% > 0.5%) |
| Asset Turnover: 0.83% > 50% (prev 1.96%; Δ -1.13% > 0%) |
| Interest Coverage Ratio: -71.15 > 6 (EBITDA TTM -154.6m / Interest Expense TTM 2.20m) |
Altman Z'' -15.00
| A: 0.63 (Total Current Assets 164.6m - Total Current Liabilities 45.7m) / Total Assets 189.8m |
| B: -2.50 (Retained Earnings -475.0m / Total Assets 189.8m) |
| C: -0.79 (EBIT TTM -156.3m / Avg Total Assets 197.1m) |
| D: -9.44 (Book Value of Equity -475.0m / Total Liabilities 50.3m) |
| Altman-Z'' Score: -19.30 = D |
What is the price of CABA shares?
Over the past week, the price has changed by -15.25%, over one month by +13.12%, over three months by -16.94% and over the past year by +5.93%.
Is CABA a buy, sell or hold?
- StrongBuy: 8
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CABA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.1 | 425.2% |
| Analysts Target Price | 13.1 | 425.2% |
| ValueRay Target Price | 2.3 | -7.2% |
CABA Fundamental Data Overview February 02, 2026
Revenue TTM = 1.64m USD
EBIT TTM = -156.3m USD
EBITDA TTM = -154.6m USD
Long Term Debt = 25.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 21.2m USD (from shortTermDebt, last quarter)
Debt = 25.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -34.4m USD (from netDebt column, last quarter)
Enterprise Value = 113.3m USD (247.4m + Debt 25.8m - CCE 159.9m)
Interest Coverage Ratio = -71.15 (Ebit TTM -156.3m / Interest Expense TTM 2.20m)
EV/FCF = -0.94x (Enterprise Value 113.3m / FCF TTM -120.3m)
FCF Yield = -106.2% (FCF TTM -120.3m / Enterprise Value 113.3m)
FCF Margin = -7342 % (FCF TTM -120.3m / Revenue TTM 1.64m)
Net Margin = -9678 % (Net Income TTM -158.5m / Revenue TTM 1.64m)
Gross Margin = -7.81% ((Revenue TTM 1.64m - Cost of Revenue TTM 1.77m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.60 (Enterprise Value 113.3m / Total Assets 189.8m)
Interest Expense / Debt = 2.27% (Interest Expense 584.0k / Debt 25.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -123.5m (EBIT -156.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.60 (Total Current Assets 164.6m / Total Current Liabilities 45.7m)
Debt / Equity = 0.18 (Debt 25.8m / totalStockholderEquity, last quarter 139.5m)
Debt / EBITDA = 0.22 (negative EBITDA) (Net Debt -34.4m / EBITDA -154.6m)
Debt / FCF = 0.29 (negative FCF - burning cash) (Net Debt -34.4m / FCF TTM -120.3m)
Total Stockholder Equity = 148.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -80.43% (Net Income -158.5m / Total Assets 189.8m)
RoE = -107.1% (Net Income TTM -158.5m / Total Stockholder Equity 148.0m)
RoCE = -89.98% (EBIT -156.3m / Capital Employed (Equity 148.0m + L.T.Debt 25.8m))
RoIC = -83.47% (negative operating profit) (NOPAT -123.5m / Invested Capital 148.0m)
WACC = 10.64% (E(247.4m)/V(273.2m) * Re(11.56%) + D(25.8m)/V(273.2m) * Rd(2.27%) * (1-Tc(0.21)))
Discount Rate = 11.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 51.70%
Fair Price DCF = unknown (Cash Flow -120.3m)
EPS Correlation: -2.35 | EPS CAGR: 26.05% | SUE: 4.0 | # QB: 2
Revenue Correlation: 15.92 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.44 | Chg30d=+0.000 | Revisions Net=-2 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.68 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+20.3% | Growth Revenue=+0.0%